Previous close | 65.48 |
Open | 65.36 |
Bid | 65.45 x 200 |
Ask | 66.08 x 100 |
Day's range | 64.58 - 65.97 |
52-week range | 36.99 - 70.81 |
Volume | |
Avg. volume | 141,498 |
Market cap | 1.384B |
Beta (5Y monthly) | 0.80 |
PE ratio (TTM) | 77.62 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.
Aptevo (APVO) plunges after it issues secondary shares, which are not only issued at a significant discount but also substantially dilute the existing shareholder base.
Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.